Viewing Study NCT04039503

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:10 PM
Ignite Modification Date: 2026-01-05 @ 5:44 AM
Study NCT ID: NCT04039503
Status: COMPLETED
Last Update Posted: 2022-01-12
First Post: 2019-07-30
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
Sponsor:
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Raw JSON

{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000098860', 'term': 'Tirzepatide'}], 'ancestors': [{'id': 'D000067757', 'term': 'Glucagon-Like Peptide-1 Receptor'}, {'id': 'D000067756', 'term': 'Glucagon-Like Peptide Receptors'}, {'id': 'D043562', 'term': 'Receptors, G-Protein-Coupled'}, {'id': 'D011956', 'term': 'Receptors, Cell Surface'}, {'id': 'D008565', 'term': 'Membrane Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D011964', 'term': 'Receptors, Gastrointestinal Hormone'}, {'id': 'D018000', 'term': 'Receptors, Peptide'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrials.gov@lilly.com', 'phone': '800-545-5979', 'title': 'Chief Medical Officer', 'organization': 'Eli Lilly and Company'}, 'certainAgreement': {'restrictionType': 'GT60', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Baseline, 17 Months', 'description': 'All randomized participants who received at least one dose of study drug. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.', 'eventGroups': [{'id': 'EG000', 'title': '5 mg Tirzepatide', 'description': '5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.', 'otherNumAtRisk': 116, 'deathsNumAtRisk': 116, 'otherNumAffected': 52, 'seriousNumAtRisk': 116, 'deathsNumAffected': 0, 'seriousNumAffected': 9}, {'id': 'EG001', 'title': '10 mg Tirzepatide', 'description': '10 mg tirzepatide administered SC once a week.', 'otherNumAtRisk': 119, 'deathsNumAtRisk': 119, 'otherNumAffected': 60, 'seriousNumAtRisk': 119, 'deathsNumAffected': 0, 'seriousNumAffected': 13}, {'id': 'EG002', 'title': '15 mg Tirzepatide', 'description': '15 mg tirzepatide administered SC once a week.', 'otherNumAtRisk': 120, 'deathsNumAtRisk': 120, 'otherNumAffected': 67, 'seriousNumAtRisk': 120, 'deathsNumAffected': 0, 'seriousNumAffected': 9}, {'id': 'EG003', 'title': 'Placebo', 'description': 'Placebo administered SC once a week.', 'otherNumAtRisk': 120, 'deathsNumAtRisk': 120, 'otherNumAffected': 58, 'seriousNumAtRisk': 120, 'deathsNumAffected': 0, 'seriousNumAffected': 10}], 'otherEvents': [{'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 8, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 9, 'numAffected': 8}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 22, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 46, 'numAffected': 15}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 44, 'numAffected': 25}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 12, 'numAffected': 12}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 9, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 12, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Eructation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 11, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 16, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 11, 'numAffected': 7}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Flatulence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 21, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 12, 'numAffected': 7}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 26, 'numAffected': 15}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 43, 'numAffected': 21}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 44, 'numAffected': 22}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 12, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 18, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 26, 'numAffected': 15}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 23, 'numAffected': 18}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 11, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 19, 'numAffected': 15}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 27, 'numAffected': 23}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Lipase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 12, 'numAffected': 10}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Decreased appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 8, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 17, 'numAffected': 15}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 21, 'numAffected': 17}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Hyperglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 18, 'numAffected': 16}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 8, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 6, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 7, 'numAffected': 7}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 7, 'numAffected': 7}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}], 'seriousEvents': [{'term': 'Acute myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Angina pectoris', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Atrial fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Cardiac failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Coronary artery disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Deafness unilateral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Abdominal hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Faecaloma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Pancreatic disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Impaired healing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Cellulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Coronavirus infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Covid-19 pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Postoperative wound infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Pyelonephritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Hip fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Humerus fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Intestinal anastomosis complication', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Spinal compression fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Hypoglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Spinal stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Synovial cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Papillary renal cell carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Renal neoplasm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Transitional cell carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Uterine cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 55, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 55, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 54, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Hypoglycaemic unconsciousness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Orthostatic intolerance', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Transient ischaemic attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Bladder disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Calculus urinary', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Chronic obstructive pulmonary disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Pulmonary embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Sleep apnoea syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Cardiac ablation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Pancreatic lesion excision', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Aortic stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}, {'term': 'Peripheral arterial occlusive disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 116, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 119, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 120, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 120, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 23.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '113', 'groupId': 'OG000'}, {'value': '117', 'groupId': 'OG001'}, {'value': '118', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': '10 mg Tirzepatide', 'description': '10 mg tirzepatide administered SC once a week.'}, {'id': 'OG001', 'title': '15 mg Tirzepatide', 'description': '15 mg tirzepatide administered SC once a week.'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Placebo administered SC once a week.'}], 'classes': [{'categories': [{'measurements': [{'value': '-2.59', 'spread': '0.081', 'groupId': 'OG000'}, {'value': '-2.59', 'spread': '0.083', 'groupId': 'OG001'}, {'value': '-0.93', 'spread': '0.079', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.66', 'ciLowerLimit': '-1.88', 'ciUpperLimit': '-1.43', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG002'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.65', 'ciLowerLimit': '-1.88', 'ciUpperLimit': '-1.43', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 40', 'description': 'HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment + Time + Treatment\\*Time (Type III sum of squares).', 'unitOfMeasure': 'Percentage of HbA1c', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomized participants from who received at least 1 dose study drug and had a baseline and at least 1 post-baseline value, excluding patients discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or prematurely stopping study drug.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in HbA1c (5 mg)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '115', 'groupId': 'OG000'}, {'value': '118', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': '5 mg Tirzepatide', 'description': '5 mg tirzepatide administered subcutaneously (SC) once a week.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Placebo administered SC once a week.'}], 'classes': [{'categories': [{'measurements': [{'value': '-2.23', 'spread': '0.081', 'groupId': 'OG000'}, {'value': '-0.93', 'spread': '0.079', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.30', 'ciLowerLimit': '-1.52', 'ciUpperLimit': '-1.07', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 40', 'description': 'HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment + Time + Treatment\\*Time (Type III sum of squares).', 'unitOfMeasure': 'Percentage of HbA1c', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomized participants who received at least one dose of 5 mg tirzepatide, placebo and had a baseline and at least 1 post-baseline value, excluding patients discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Body Weight', 'denoms': [{'units': 'Participants', 'counts': [{'value': '115', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '117', 'groupId': 'OG002'}, {'value': '118', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': '5 mg Tirzepatide', 'description': '5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.'}, {'id': 'OG001', 'title': '10 mg Tirzepatide', 'description': '10 mg tirzepatide administered SC once a week.'}, {'id': 'OG002', 'title': '15 mg Tirzepatide', 'description': '15 mg tirzepatide administered SC once a week.'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Placebo administered SC once a week.'}], 'classes': [{'categories': [{'measurements': [{'value': '-6.2', 'spread': '0.58', 'groupId': 'OG000'}, {'value': '-8.2', 'spread': '0.58', 'groupId': 'OG001'}, {'value': '-10.9', 'spread': '0.59', 'groupId': 'OG002'}, {'value': '1.7', 'spread': '0.57', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-7.8', 'ciLowerLimit': '-9.4', 'ciUpperLimit': '-6.3', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-9.9', 'ciLowerLimit': '-11.5', 'ciUpperLimit': '-8.3', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-12.6', 'ciLowerLimit': '-14.2', 'ciUpperLimit': '-11.0', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 40', 'description': 'Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline HbA1c Group (\\<= 8.0%, \\>8.0%) + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment + Time + Treatment\\*Time (Type III sum of squares).', 'unitOfMeasure': 'Kilograms (kg)', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomly assigned participants who took at least 1 dose of study drug and had a baseline and at least 1 post-baseline value, excluding patients discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or prematurely stopping study drug.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving an HbA1c Target Value of <7%', 'denoms': [{'units': 'Participants', 'counts': [{'value': '115', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '117', 'groupId': 'OG002'}, {'value': '118', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': '5 mg Tirzepatide', 'description': '5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.'}, {'id': 'OG001', 'title': '10 mg Tirzepatide', 'description': '10 mg tirzepatide administered SC once a week.'}, {'id': 'OG002', 'title': '15 mg Tirzepatide', 'description': '15 mg tirzepatide administered SC once a week.'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Placebo administered SC once a week.'}], 'classes': [{'categories': [{'measurements': [{'value': '93.04', 'groupId': 'OG000'}, {'value': '97.35', 'groupId': 'OG001'}, {'value': '94.02', 'groupId': 'OG002'}, {'value': '33.90', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '37.77', 'ciLowerLimit': '15.23', 'ciUpperLimit': '93.70', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '100.07', 'ciLowerLimit': '30.02', 'ciUpperLimit': '333.62', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '43.31', 'ciLowerLimit': '16.92', 'ciUpperLimit': '110.83', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 40', 'description': 'Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A.HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomly assigned participants who took at least 1 dose of study drug and had a baseline and at least 1 post-baseline value, excluding patients discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or prematurely stopping study drug.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Serum Glucose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '115', 'groupId': 'OG000'}, {'value': '116', 'groupId': 'OG001'}, {'value': '118', 'groupId': 'OG002'}, {'value': '118', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': '5 mg Tirzepatide', 'description': '5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.'}, {'id': 'OG001', 'title': '10 mg Tirzepatide', 'description': '10 mg tirzepatide administered SC once a week.'}, {'id': 'OG002', 'title': '15 mg Tirzepatide', 'description': '15 mg tirzepatide administered SC once a week.'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Placebo administered SC once a week.'}], 'classes': [{'categories': [{'measurements': [{'value': '-61.4', 'spread': '2.55', 'groupId': 'OG000'}, {'value': '-67.9', 'spread': '2.55', 'groupId': 'OG001'}, {'value': '-67.7', 'spread': '2.64', 'groupId': 'OG002'}, {'value': '-38.9', 'spread': '2.49', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-22.5', 'ciLowerLimit': '-29.5', 'ciUpperLimit': '-15.4', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-29.0', 'ciLowerLimit': '-36.0', 'ciUpperLimit': '-22.0', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-28.8', 'ciLowerLimit': '-35.9', 'ciUpperLimit': '-21.6', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 40', 'description': 'Fasting serum glucose (FSG) is a test to determine sugar levels in serum sample after an overnight fast. LS Mean was determined by MMRM model with Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\\<= 8.0%, \\>8.0%) + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables.', 'unitOfMeasure': 'milligram per Deciliter (mg/dL)', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomly assigned participants who took at least 1 dose of study drug and had a baseline and at least 1 post-baseline value, excluding patients discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or prematurely stopping study drug.'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '94', 'groupId': 'OG002'}, {'value': '97', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': '5 mg Tirzepatide', 'description': '5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.'}, {'id': 'OG001', 'title': '10 mg Tirzepatide', 'description': '10 mg tirzepatide administered SC once a week.'}, {'id': 'OG002', 'title': '15 mg Tirzepatide', 'description': '15 mg tirzepatide administered SC once a week.'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Placebo administered SC once a week.'}], 'classes': [{'categories': [{'measurements': [{'value': '-67.1', 'spread': '2.05', 'groupId': 'OG000'}, {'value': '-71.7', 'spread': '2.04', 'groupId': 'OG001'}, {'value': '-73.7', 'spread': '2.10', 'groupId': 'OG002'}, {'value': '-39.4', 'spread': '2.07', 'groupId': 'OG003'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 40', 'description': 'The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Postmeal, Midday Premeal, Midday 2-hour Postmeal, Evening Premeal, Evening 2-hour Postmeal and Bedtime. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline HbA1c Group (\\<= 8.0%, \\>8.0%) + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment (Type III sum of squares).', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomly assigned participants who took at least 1 dose of study drug and had a baseline and at least 1 post-baseline value, excluding patients discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or prematurely stopping study drug.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Achieved Weight Loss ≥5%', 'denoms': [{'units': 'Participants', 'counts': [{'value': '115', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '117', 'groupId': 'OG002'}, {'value': '118', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': '5 mg Tirzepatide', 'description': '5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.'}, {'id': 'OG001', 'title': '10 mg Tirzepatide', 'description': '10 mg tirzepatide administered SC once a week.'}, {'id': 'OG002', 'title': '15 mg Tirzepatide', 'description': '15 mg tirzepatide administered SC once a week.'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Placebo administered SC once a week.'}], 'classes': [{'categories': [{'measurements': [{'value': '53.91', 'groupId': 'OG000'}, {'value': '64.60', 'groupId': 'OG001'}, {'value': '84.62', 'groupId': 'OG002'}, {'value': '5.93', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '17.15', 'ciLowerLimit': '7.55', 'ciUpperLimit': '38.93', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '27.24', 'ciLowerLimit': '11.87', 'ciUpperLimit': '62.55', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '79.61', 'ciLowerLimit': '32.76', 'ciUpperLimit': '193.44', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 40', 'description': 'Percentage of Participants who Achieved Weight Loss ≥5%.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomly assigned participants who took at least 1 dose of study drug and had a baseline and at least 1 post-baseline value, excluding patients discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or prematurely stopping study drug.'}, {'type': 'SECONDARY', 'title': 'Percentage Change From Baseline in Daily Mean Insulin Glargine Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '105', 'groupId': 'OG000'}, {'value': '103', 'groupId': 'OG001'}, {'value': '96', 'groupId': 'OG002'}, {'value': '111', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': '5 mg Tirzepatide', 'description': '5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.'}, {'id': 'OG001', 'title': '10 mg Tirzepatide', 'description': '10 mg tirzepatide administered SC once a week.'}, {'id': 'OG002', 'title': '15 mg Tirzepatide', 'description': '15 mg tirzepatide administered SC once a week.'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Placebo administered SC once a week.'}], 'classes': [{'categories': [{'measurements': [{'value': '13.0', 'spread': '7.34', 'groupId': 'OG000'}, {'value': '8.1', 'spread': '7.03', 'groupId': 'OG001'}, {'value': '-11.4', 'spread': '5.85', 'groupId': 'OG002'}, {'value': '75.0', 'spread': '11.11', 'groupId': 'OG003'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Estimate Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-35.4', 'ciLowerLimit': '-46.0', 'ciUpperLimit': '-22.8', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG001', 'OG003'], 'paramType': 'Estimate Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-38.2', 'ciLowerLimit': '-48.3', 'ciUpperLimit': '-26.1', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG002', 'OG003'], 'paramType': 'Estimate Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-49.3', 'ciLowerLimit': '-57.7', 'ciUpperLimit': '-39.4', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 40', 'description': 'LS mean was calculated using MMRM model with log (Baseline) + Baseline Metformin Use (Yes, No) + Pooled Country + Baseline HbA1c Group (\\<= 8.0%, \\>8.0%) + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables.', 'unitOfMeasure': 'International Units (IU)', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomly assigned participants who took at least 1 dose of study drug and had a baseline and at least 1 post-baseline value, excluding patients discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or prematurely stopping study drug.'}, {'type': 'SECONDARY', 'title': 'Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 Millimole/Liter (mmol/L)] or Severe Hypoglycemia', 'denoms': [{'units': 'Participants', 'counts': [{'value': '116', 'groupId': 'OG000'}, {'value': '119', 'groupId': 'OG001'}, {'value': '120', 'groupId': 'OG002'}, {'value': '120', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': '5 mg Tirzepatide', 'description': '5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.'}, {'id': 'OG001', 'title': '10 mg Tirzepatide', 'description': '10 mg tirzepatide administered SC once a week.'}, {'id': 'OG002', 'title': '15 mg Tirzepatide', 'description': '15 mg tirzepatide administered SC once a week.'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Placebo administered SC once a week.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.49', 'spread': '0.141', 'groupId': 'OG000'}, {'value': '0.66', 'spread': '0.169', 'groupId': 'OG001'}, {'value': '0.38', 'spread': '0.099', 'groupId': 'OG002'}, {'value': '0.51', 'spread': '0.149', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline through Safety Follow-Up (Up to Week 44)', 'description': 'The hypoglycemia events were defined by participant reported events with blood glucose \\<54mg/dL) (\\<3.0 mmol/L\\] or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of postbaseline hypoglycemia was estimated by negative binomial model: number of episodes = Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\\<= 8.0%, \\>8.0%) + Treatment, with log (exposure in days/365.25) as an offset variable.', 'unitOfMeasure': 'Episodes/participant/365.25 days', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomly assigned participants who took at least 1 dose of study drug.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide', 'denoms': [{'units': 'Participants', 'counts': [{'value': '115', 'groupId': 'OG000'}, {'value': '116', 'groupId': 'OG001'}, {'value': '118', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': '5 mg Tirzepatide', 'description': '5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.'}, {'id': 'OG001', 'title': '10 mg Tirzepatide', 'description': '10 mg tirzepatide administered SC once a week.'}, {'id': 'OG002', 'title': '15 mg Tirzepatide', 'description': '15 mg tirzepatide administered SC once a week.'}], 'classes': [{'categories': [{'measurements': [{'value': '79700', 'spread': '24.5', 'groupId': 'OG000'}, {'value': '164000', 'spread': '26.7', 'groupId': 'OG001'}, {'value': '246000', 'spread': '26.4', 'groupId': 'OG002'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Week 7, 15, 23 and 39 post dose', 'description': 'AUC is a combined measure obtained from Week 7, 15, 23 and 39 and a single averaged measure of AUC was reported.', 'unitOfMeasure': 'nanogram*hour per milliliter (ng*h/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomized participants who received at least one dose and had evaluable PK data.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving an HbA1c Target Value of <5.7%', 'denoms': [{'units': 'Participants', 'counts': [{'value': '115', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '117', 'groupId': 'OG002'}, {'value': '118', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': '5 mg Tirzepatide', 'description': '5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.'}, {'id': 'OG001', 'title': '10 mg Tirzepatide', 'description': '10 mg tirzepatide administered SC once a week.'}, {'id': 'OG002', 'title': '15 mg Tirzepatide', 'description': '15 mg tirzepatide administered SC once a week.'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Placebo administered SC once a week.'}], 'classes': [{'categories': [{'measurements': [{'value': '26.09', 'groupId': 'OG000'}, {'value': '47.79', 'groupId': 'OG001'}, {'value': '62.39', 'groupId': 'OG002'}, {'value': '2.54', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '12.22', 'ciLowerLimit': '3.93', 'ciUpperLimit': '38.00', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '32.36', 'ciLowerLimit': '10.52', 'ciUpperLimit': '99.49', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '56.26', 'ciLowerLimit': '18.27', 'ciUpperLimit': '173.26', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 40', 'description': 'Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomly assigned participants who took at least 1 dose of study drug and had a baseline and at least 1 post-baseline value, excluding patients discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or prematurely stopping study drug'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': '5 mg Tirzepatide', 'description': '5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.'}, {'id': 'FG001', 'title': '10 mg Tirzepatide', 'description': '10 mg tirzepatide administered SC once a week.'}, {'id': 'FG002', 'title': '15 mg Tirzepatide', 'description': '15 mg tirzepatide administered SC once a week.'}, {'id': 'FG003', 'title': 'Placebo', 'description': 'Placebo administered SC once a week.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '116'}, {'groupId': 'FG001', 'numSubjects': '119'}, {'groupId': 'FG002', 'numSubjects': '120'}, {'groupId': 'FG003', 'numSubjects': '120'}]}, {'type': 'Received at Least One Dose of Study Drug', 'achievements': [{'groupId': 'FG000', 'numSubjects': '116'}, {'groupId': 'FG001', 'numSubjects': '119'}, {'groupId': 'FG002', 'numSubjects': '120'}, {'groupId': 'FG003', 'numSubjects': '120'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '109'}, {'groupId': 'FG001', 'numSubjects': '115'}, {'groupId': 'FG002', 'numSubjects': '110'}, {'groupId': 'FG003', 'numSubjects': '117'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '7'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '10'}, {'groupId': 'FG003', 'numSubjects': '3'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '2'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '116', 'groupId': 'BG000'}, {'value': '119', 'groupId': 'BG001'}, {'value': '120', 'groupId': 'BG002'}, {'value': '120', 'groupId': 'BG003'}, {'value': '475', 'groupId': 'BG004'}]}], 'groups': [{'id': 'BG000', 'title': '5 mg Tirzepatide', 'description': '5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.'}, {'id': 'BG001', 'title': '10 mg Tirzepatide', 'description': '10 mg tirzepatide administered SC once a week.'}, {'id': 'BG002', 'title': '15 mg Tirzepatide', 'description': '15 mg tirzepatide administered SC once a week.'}, {'id': 'BG003', 'title': 'Placebo', 'description': 'Placebo administered SC once a week.'}, {'id': 'BG004', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '61.50', 'spread': '9.81', 'groupId': 'BG000'}, {'value': '60.40', 'spread': '10.24', 'groupId': 'BG001'}, {'value': '60.50', 'spread': '9.92', 'groupId': 'BG002'}, {'value': '60.00', 'spread': '9.63', 'groupId': 'BG003'}, {'value': '60.60', 'spread': '9.88', 'groupId': 'BG004'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '55', 'groupId': 'BG000'}, {'value': '47', 'groupId': 'BG001'}, {'value': '55', 'groupId': 'BG002'}, {'value': '54', 'groupId': 'BG003'}, {'value': '211', 'groupId': 'BG004'}]}, {'title': 'Male', 'measurements': [{'value': '61', 'groupId': 'BG000'}, {'value': '72', 'groupId': 'BG001'}, {'value': '65', 'groupId': 'BG002'}, {'value': '66', 'groupId': 'BG003'}, {'value': '264', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}, {'value': '5', 'groupId': 'BG003'}, {'value': '22', 'groupId': 'BG004'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '94', 'groupId': 'BG000'}, {'value': '95', 'groupId': 'BG001'}, {'value': '93', 'groupId': 'BG002'}, {'value': '98', 'groupId': 'BG003'}, {'value': '380', 'groupId': 'BG004'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '18', 'groupId': 'BG000'}, {'value': '16', 'groupId': 'BG001'}, {'value': '22', 'groupId': 'BG002'}, {'value': '17', 'groupId': 'BG003'}, {'value': '73', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}]}, {'title': 'Asian', 'measurements': [{'value': '20', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '22', 'groupId': 'BG002'}, {'value': '22', 'groupId': 'BG003'}, {'value': '85', 'groupId': 'BG004'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Black or African American', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '6', 'groupId': 'BG004'}]}, {'title': 'White', 'measurements': [{'value': '95', 'groupId': 'BG000'}, {'value': '94', 'groupId': 'BG001'}, {'value': '94', 'groupId': 'BG002'}, {'value': '97', 'groupId': 'BG003'}, {'value': '380', 'groupId': 'BG004'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'Czechia', 'categories': [{'measurements': [{'value': '24', 'groupId': 'BG000'}, {'value': '24', 'groupId': 'BG001'}, {'value': '23', 'groupId': 'BG002'}, {'value': '23', 'groupId': 'BG003'}, {'value': '94', 'groupId': 'BG004'}]}]}, {'title': 'Germany', 'categories': [{'measurements': [{'value': '32', 'groupId': 'BG000'}, {'value': '32', 'groupId': 'BG001'}, {'value': '33', 'groupId': 'BG002'}, {'value': '32', 'groupId': 'BG003'}, {'value': '129', 'groupId': 'BG004'}]}]}, {'title': 'Japan', 'categories': [{'measurements': [{'value': '19', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}, {'value': '22', 'groupId': 'BG003'}, {'value': '82', 'groupId': 'BG004'}]}]}, {'title': 'Poland', 'categories': [{'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}, {'value': '9', 'groupId': 'BG003'}, {'value': '36', 'groupId': 'BG004'}]}]}, {'title': 'Puerto Rico', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '12', 'groupId': 'BG004'}]}]}, {'title': 'Slovakia', 'categories': [{'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '8', 'groupId': 'BG003'}, {'value': '31', 'groupId': 'BG004'}]}]}, {'title': 'Spain', 'categories': [{'measurements': [{'value': '13', 'groupId': 'BG000'}, {'value': '15', 'groupId': 'BG001'}, {'value': '15', 'groupId': 'BG002'}, {'value': '14', 'groupId': 'BG003'}, {'value': '57', 'groupId': 'BG004'}]}]}, {'title': 'United States', 'categories': [{'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}, {'value': '9', 'groupId': 'BG003'}, {'value': '34', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}, {'title': 'Hemoglobin A1c', 'classes': [{'categories': [{'measurements': [{'value': '8.30', 'spread': '0.88', 'groupId': 'BG000'}, {'value': '8.36', 'spread': '0.83', 'groupId': 'BG001'}, {'value': '8.23', 'spread': '0.86', 'groupId': 'BG002'}, {'value': '8.37', 'spread': '0.84', 'groupId': 'BG003'}, {'value': '8.31', 'spread': '0.85', 'groupId': 'BG004'}]}]}], 'paramType': 'MEAN', 'description': 'HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time.', 'unitOfMeasure': 'Percentage of HbA1c', 'dispersionType': 'STANDARD_DEVIATION'}], 'populationDescription': 'All randomized participants.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2020-06-26', 'size': 8822303, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2021-07-07T02:23', 'hasProtocol': True}, {'date': '2021-02-01', 'size': 7047505, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2021-07-07T02:18', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 475}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2019-08-30', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-12-01', 'completionDateStruct': {'date': '2021-01-13', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-12-12', 'studyFirstSubmitDate': '2019-07-30', 'resultsFirstSubmitDate': '2021-12-12', 'studyFirstSubmitQcDate': '2019-07-30', 'lastUpdatePostDateStruct': {'date': '2022-01-12', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2021-12-12', 'studyFirstPostDateStruct': {'date': '2019-07-31', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2022-01-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-12-22', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)', 'timeFrame': 'Baseline, Week 40', 'description': 'HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment + Time + Treatment\\*Time (Type III sum of squares).'}], 'secondaryOutcomes': [{'measure': 'Change From Baseline in HbA1c (5 mg)', 'timeFrame': 'Baseline, Week 40', 'description': 'HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment + Time + Treatment\\*Time (Type III sum of squares).'}, {'measure': 'Change From Baseline in Body Weight', 'timeFrame': 'Baseline, Week 40', 'description': 'Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline HbA1c Group (\\<= 8.0%, \\>8.0%) + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment + Time + Treatment\\*Time (Type III sum of squares).'}, {'measure': 'Percentage of Participants Achieving an HbA1c Target Value of <7%', 'timeFrame': 'Week 40', 'description': 'Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A.HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.'}, {'measure': 'Change From Baseline in Fasting Serum Glucose', 'timeFrame': 'Baseline, Week 40', 'description': 'Fasting serum glucose (FSG) is a test to determine sugar levels in serum sample after an overnight fast. LS Mean was determined by MMRM model with Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\\<= 8.0%, \\>8.0%) + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables.'}, {'measure': 'Mean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values', 'timeFrame': 'Baseline, Week 40', 'description': 'The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Postmeal, Midday Premeal, Midday 2-hour Postmeal, Evening Premeal, Evening 2-hour Postmeal and Bedtime. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline HbA1c Group (\\<= 8.0%, \\>8.0%) + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment (Type III sum of squares).'}, {'measure': 'Percentage of Participants Who Achieved Weight Loss ≥5%', 'timeFrame': 'Week 40', 'description': 'Percentage of Participants who Achieved Weight Loss ≥5%.'}, {'measure': 'Percentage Change From Baseline in Daily Mean Insulin Glargine Dose', 'timeFrame': 'Baseline, Week 40', 'description': 'LS mean was calculated using MMRM model with log (Baseline) + Baseline Metformin Use (Yes, No) + Pooled Country + Baseline HbA1c Group (\\<= 8.0%, \\>8.0%) + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables.'}, {'measure': 'Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 Millimole/Liter (mmol/L)] or Severe Hypoglycemia', 'timeFrame': 'Baseline through Safety Follow-Up (Up to Week 44)', 'description': 'The hypoglycemia events were defined by participant reported events with blood glucose \\<54mg/dL) (\\<3.0 mmol/L\\] or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of postbaseline hypoglycemia was estimated by negative binomial model: number of episodes = Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\\<= 8.0%, \\>8.0%) + Treatment, with log (exposure in days/365.25) as an offset variable.'}, {'measure': 'Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide', 'timeFrame': 'Week 7, 15, 23 and 39 post dose', 'description': 'AUC is a combined measure obtained from Week 7, 15, 23 and 39 and a single averaged measure of AUC was reported.'}, {'measure': 'Percentage of Participants Achieving an HbA1c Target Value of <5.7%', 'timeFrame': 'Week 40', 'description': 'Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['glucose-dependent insulinotropic polypeptide (GIP)', 'glucagon-like peptide-1 (GLP-1)', 'GIP/GLP-1 dual receptor agonist', 'T2DM'], 'conditions': ['Type 2 Diabetes']}, 'referencesModule': {'references': [{'pmid': '39531161', 'type': 'DERIVED', 'citation': 'De Block C, Peleshok J, Wilding JPH, Kwan AYM, Rasouli N, Maldonado JM, Wysham C, Liu M, Aleppo G, Benneyworth BD. Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics. Diabetes Ther. 2025 Jan;16(1):43-71. doi: 10.1007/s13300-024-01660-0. Epub 2024 Nov 12.'}, {'pmid': '37668888', 'type': 'DERIVED', 'citation': 'Boye KS, Sapin H, Dong W, Williamson S, Lee CJ, Thieu VT. Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide. Diabetes Ther. 2023 Nov;14(11):1867-1887. doi: 10.1007/s13300-023-01457-7. Epub 2023 Sep 5.'}, {'pmid': '37526908', 'type': 'DERIVED', 'citation': 'Boye KS, Thieu VT, Sapin H, Lee CJ, Lando LF, Brown K, Bray R, Wiese RJ, Patel H, Rodriguez A, Yu M. Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme. Diabetes Ther. 2023 Nov;14(11):1833-1852. doi: 10.1007/s13300-023-01451-z. Epub 2023 Aug 1.'}, {'pmid': '35210595', 'type': 'DERIVED', 'citation': 'Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, Zoungas S. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022 Mar;28(3):591-598. doi: 10.1038/s41591-022-01707-4. Epub 2022 Feb 24.'}, {'pmid': '35133415', 'type': 'DERIVED', 'citation': 'Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodriguez A. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):534-545. doi: 10.1001/jama.2022.0078.'}], 'seeAlsoLinks': [{'url': 'https://trials.lillytrialguide.com/en-US/trial/33Mn9pqfndRwZEPVvpNxDR', 'label': 'A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin. Participants will administer tirzepatide or placebo along with their previous glucose lowering medications. The study will last approximately 47 weeks and may include about 23 visits.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Have been diagnosed with type 2 diabetes mellitus (T2DM) and have been treated with insulin glargine (U100), once daily with or without metformin ≥3 months prior to screening visit.\n* Have HbA1c between ≥7.0% and ≤10.5%.\n* Have a stable weight (± 5%) for at least 3 months before screening.\n* Have a body mass index (BMI) ≥23 kilograms per meter squared (kg/m²) at screening.\n\nExclusion Criteria:\n\n* Have type 1 diabetes mellitus.\n* Have had chronic or acute pancreatitis any time prior to study entry.\n* Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring acute treatment.\n* Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss.\n* Have an estimated glomerular filtration rate \\<30 mL/minute/1.73 m² \\[for participants on metformin, estimated glomerular filtration rate \\<45 mL/min/1.73 m2 (or lower than the country-specific threshold for using the protocol-required dose of metformin per local label)\\]\n* Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months.\n* Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2.\n* Have been taking weight loss drugs, including over-the-counter medications during the last 3 months.'}, 'identificationModule': {'nctId': 'NCT04039503', 'acronym': 'SURPASS-5', 'briefTitle': 'A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin', 'organization': {'class': 'INDUSTRY', 'fullName': 'Eli Lilly and Company'}, 'officialTitle': 'Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide Versus Placebo in Patients With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin', 'orgStudyIdInfo': {'id': '16998'}, 'secondaryIdInfos': [{'id': 'I8F-MC-GPGI', 'type': 'OTHER', 'domain': 'Eli Lilly and Company'}, {'id': '2019-000860-99', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': '5 mg Tirzepatide', 'description': '5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.', 'interventionNames': ['Drug: Tirzepatide']}, {'type': 'EXPERIMENTAL', 'label': '10 mg Tirzepatide', 'description': '10 mg tirzepatide administered SC once a week.', 'interventionNames': ['Drug: Tirzepatide']}, {'type': 'EXPERIMENTAL', 'label': '15 mg Tirzepatide', 'description': '15 mg tirzepatide administered SC once a week.', 'interventionNames': ['Drug: Tirzepatide']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Placebo administered SC once a week.', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Tirzepatide', 'type': 'DRUG', 'otherNames': ['LY3298176'], 'description': 'Administered SC as add-on to the pre-trial background medication.', 'armGroupLabels': ['10 mg Tirzepatide', '15 mg Tirzepatide', '5 mg Tirzepatide']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Administered SC as add-on to the pre-trial background medication.', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '93720', 'city': 'Fresno', 'state': 'California', 'country': 'United States', 'facility': 'Valley Endocrine, Fresno', 'geoPoint': {'lat': 36.74773, 'lon': -119.77237}}, {'zip': '34652', 'city': 'New Port Richey', 'state': 'Florida', 'country': 'United States', 'facility': 'Sun Coast Clinical Research, Inc', 'geoPoint': {'lat': 28.24418, 'lon': -82.71927}}, {'zip': '03063', 'city': 'Nashua', 'state': 'New Hampshire', 'country': 'United States', 'facility': 'Southern New Hampshire Diabetes and Endocrinology', 'geoPoint': {'lat': 42.76537, 'lon': -71.46757}}, {'zip': '10016', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Manhattan Medical Research', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '73069', 'city': 'Norman', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Intend Research', 'geoPoint': {'lat': 35.22257, 'lon': -97.43948}}, {'zip': '26201', 'city': 'Příbram', 'state': 'Central Bohemia', 'country': 'Czechia', 'facility': 'Milan Kvapil s.r.o.', 'geoPoint': {'lat': 49.68988, 'lon': 14.01043}}, {'zip': '25001', 'city': 'Brandys Nad Labem-Stara Bolesl', 'country': 'Czechia', 'facility': 'Diacentrum Brandys n.L. s.r.o.'}, {'zip': '79401', 'city': 'Krnov', 'country': 'Czechia', 'facility': 'Diabetologicka ordinace pro dospele', 'geoPoint': {'lat': 50.08967, 'lon': 17.70385}}, {'zip': '53002', 'city': 'Pardubice', 'country': 'Czechia', 'facility': 'Diahelp s.r.o., Interni a diabetologicka ambulance', 'geoPoint': {'lat': 50.04075, 'lon': 15.77659}}, {'zip': '11000', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Lekarna Dr. Max', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '149 00', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Milan Kvapil s.r.o.', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '181 00', 'city': 'Prague', 'country': 'Czechia', 'facility': 'RESTRIAL s.r.o.', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '14612', 'city': 'Falkensee', 'state': 'Brandenburg', 'country': 'Germany', 'facility': 'Praxis Dr. Jörg Lüdemann', 'geoPoint': {'lat': 52.56014, 'lon': 13.0927}}, {'zip': '35415', 'city': 'Pohlheim', 'state': 'Hesse', 'country': 'Germany', 'facility': 'Arztpraxis Dr. Cornelia Marck'}, {'zip': '45136', 'city': 'Essen', 'state': 'North Rhine-Westphalia', 'country': 'Germany', 'facility': 'InnoDiab Forschung GmbH', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'zip': '48145', 'city': 'Münster', 'state': 'North Rhine-Westphalia', 'country': 'Germany', 'facility': 'Institut für Diabetesforschung Münster GmbH', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}}, {'zip': '67059', 'city': 'Ludwigshafen am Rhein', 'state': 'Rhineland-Palatinate', 'country': 'Germany', 'facility': 'Praxis Dr. Kempe - Dr. Stemler', 'geoPoint': {'lat': 49.48121, 'lon': 8.44641}}, {'zip': '66386', 'city': 'Saint Ingbert-Oberwürzbach', 'state': 'Saarland', 'country': 'Germany', 'facility': 'Schwerpunktpraxis Diabetes'}, {'zip': '39112', 'city': 'Magdeburg', 'state': 'Saxony-Anhalt', 'country': 'Germany', 'facility': 'SMO.MD GmbH', 'geoPoint': {'lat': 52.13129, 'lon': 11.63189}}, {'zip': '23758', 'city': 'Oldenburg in Holstein', 'state': 'Schleswig-Holstein', 'country': 'Germany', 'facility': 'RED-Institut GmbH', 'geoPoint': {'lat': 54.29498, 'lon': 10.89043}}, {'zip': '21073', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Diabetologische Schwerpunktpraxis B. Scholz/Dr. B. Paschen', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '22607', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Gemeinschaftspraxis für innere Medizin und Diabetologie', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '277-0825', 'city': 'Kashiwa', 'state': 'Chiba', 'country': 'Japan', 'facility': 'Kashiwa hospital', 'geoPoint': {'lat': 35.86224, 'lon': 139.97732}}, {'zip': '060-0062', 'city': 'Sapporo', 'state': 'Hokkaido', 'country': 'Japan', 'facility': 'Manda Hospital', 'geoPoint': {'lat': 43.06667, 'lon': 141.35}}, {'zip': '247-0056', 'city': 'Kamakura', 'state': 'Kanagawa', 'country': 'Japan', 'facility': 'Takai Naika Clinic', 'geoPoint': {'lat': 35.31085, 'lon': 139.54698}}, {'zip': '569-1096', 'city': 'Takatsuki', 'state': 'Osaka', 'country': 'Japan', 'facility': 'Takatsuki Red Cross Hospital', 'geoPoint': {'lat': 34.84833, 'lon': 135.61678}}, {'zip': '103-0027', 'city': 'Chuo-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Tokyo-Eki Center-building Clinic'}, {'zip': '103-0028', 'city': 'Chuo-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Tokyo Center Clinic'}, {'zip': '104-0031', 'city': 'Chuo-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Tokyo Clinical Trial Centre Fukuwa Clinic'}, {'zip': '1030002', 'city': 'Chuou-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'The Institute for Adult Diseases, Asahi Life Foundation'}, {'zip': '143-0015', 'city': 'Ōta-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Sato Naika Clinic', 'geoPoint': {'lat': 35.56126, 'lon': 139.71605}}, {'zip': '862-0976', 'city': 'Kumamoto', 'country': 'Japan', 'facility': 'Jinnouchi Hospital', 'geoPoint': {'lat': 32.80589, 'lon': 130.69181}}, {'zip': '01-518', 'city': 'Warsaw', 'state': 'Masovian Voivodeship', 'country': 'Poland', 'facility': 'Centrum Medyczne AMED', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '15-351', 'city': 'Bialystok', 'state': 'Podlaskie Voivodeship', 'country': 'Poland', 'facility': 'NZOZ ZDROWIE Osteo-Medic', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'zip': '80-546', 'city': 'Gdansk', 'state': 'Pomeranian Voivodeship', 'country': 'Poland', 'facility': 'Centrum Badan Klinicznych, PI House', 'geoPoint': {'lat': 54.35227, 'lon': 18.64912}}, {'zip': '20-538', 'city': 'Lublin', 'country': 'Poland', 'facility': 'NZOZ Przychodnia Specjalistyczna MEDICA', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'zip': '00725', 'city': 'Caguas', 'state': 'PR', 'country': 'Puerto Rico', 'facility': 'Centro de Endocrinologia y Nutricion del Turabo', 'geoPoint': {'lat': 18.23412, 'lon': -66.0485}}, {'zip': '00674', 'city': 'Manatí', 'state': 'PR', 'country': 'Puerto Rico', 'facility': 'Manati Center for Clinical Research Inc', 'geoPoint': {'lat': 18.42745, 'lon': -66.49212}}, {'zip': '98101', 'city': 'Hnúšťa', 'country': 'Slovakia', 'facility': 'Ambulancia vnútorného lekárstva Hnúša (Diabetes care)', 'geoPoint': {'lat': 48.57257, 'lon': 19.95395}}, {'zip': '901 01', 'city': 'Malacky', 'country': 'Slovakia', 'facility': 'Sin Azucar', 'geoPoint': {'lat': 48.43604, 'lon': 17.02188}}, {'zip': '971 01', 'city': 'Prievidza', 'country': 'Slovakia', 'facility': 'Dia-Clarus.s.r.o.', 'geoPoint': {'lat': 48.77446, 'lon': 18.6275}}, {'zip': '917 01', 'city': 'Trnava', 'country': 'Slovakia', 'facility': 'JAL', 'geoPoint': {'lat': 48.37773, 'lon': 17.58603}}, {'zip': '01001', 'city': 'Žilina', 'country': 'Slovakia', 'facility': 'Medivasa, s.r.o.', 'geoPoint': {'lat': 49.22315, 'lon': 18.73941}}, {'zip': '29010', 'city': 'Málaga', 'state': 'Andalusia', 'country': 'Spain', 'facility': 'Hospital Clinico Universitario Virgen de la Victoria', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'zip': '46600', 'city': 'Alzira', 'state': 'Valencia', 'country': 'Spain', 'facility': 'Hospital de la Ribera', 'geoPoint': {'lat': 39.15, 'lon': -0.43333}}, {'zip': '41009', 'city': 'Seville', 'country': 'Spain', 'facility': 'Hospital Universitario Virgen Macarena', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '41010', 'city': 'Seville', 'country': 'Spain', 'facility': 'Hospital Infanta Luisa', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '46026', 'city': 'Valencia', 'country': 'Spain', 'facility': 'Hospital Universitari i Politecnic La Fe-ENDO', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}], 'overallOfficials': [{'name': 'Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Eli Lilly and Company'}]}, 'ipdSharingStatementModule': {'url': 'http://vivli.org/', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'CSR'], 'timeFrame': 'Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.', 'ipdSharing': 'YES', 'description': 'Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.', 'accessCriteria': 'A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Eli Lilly and Company', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}